Tag - GERN

Developments

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

Geron (NASDAQ:GERN) reported that its Phase 3 IMpactMF clinical trial, which is evaluating imetelstat for the treatment of refractory myelofibrosis, is open for patient screening and enrollment. The trial is designed to...

December 11, 2020

Markets

Stifel starts Geron at buy; PT $3

Stifel initiated coverage of Geron (NASDAQ:GERN) with a “buy” rating and $3 price target. The stock closed at $1.59 on July 31. Geron is focused on the development and potential commercialization of a single product...

August 3, 2020

Developments

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Geron (NASDAQ:GERN) dosed the first patient in its Phase 3 clinical trial evaluating imetelstat, a telomerase inhibitor, in lower risk myelodysplastic syndromes (MDSs). MDSs occur when bone marrow cells do not mature...

October 11, 2019

Developments

Geron imetelstat gets FDA fast track designation for myelofibrosis

Geron’s (NASDAQ:GERN) imetelstat, a telomerase inhibitor, received FDA fast track designation for the treatment of relapsed/refractory myelofibrosis (MF). MF is a chronic blood cancer that impairs normal blood...

September 30, 2019

Tag - GERN

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

Stifel starts Geron at buy; PT $3

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Geron imetelstat gets FDA fast track designation for myelofibrosis

General

More